Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL145650 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL3406205 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL29360959 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13764364 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13785162 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL34339 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1649712 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL40651 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1720497 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL2755938 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| WO-2008090357-A2 | N, N; -SUBSTITUTED PIPERAZINES BINDING TO MELANOCORTIN RECEPTOR | PALATIN TECHNOLOGIES, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | MAOB 4262/4885MAOA 4546/4885KDM1A 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.